The prostate cancer marker PSA activates blood vessels and lymphangiogenesis factors and promotes cancer metastasis

  In a new study, prostate-specific antigen (PSA) is a marker of prostate cancer and one of the catalysts that activates vascular endothelial cells and lymphangiogenesis factors, which may help the spread of cancer.

  The University of Helsinki (University of Helsinki) led a research team led by Dr. Michael Jeltsch (Michael Jeltsch) and his partners, and discovered a new type of VEGF-C and VEGF-D that activates vascular endothelial and lymphangiogenic growth factors mechanism. These growth factors not only play an important role in fetal development, but also play an important role in cancer spread and metastasis formation. Most deaths caused by cancer, including prostate cancer, are caused by metastases. In order to find a way to prohibit or stop this process, you need to understand the key factors related to the sequence of events that led to the transfer. Researchers have discovered two new proteolytic enzymes (prostheses) that can simultaneously activate the growth factors VEGF-C and VEGF-D. One of these enzymes is prostate specific antigen (PSA), which can also be used as a marker for prostate cancer. In addition to the prostate, VEGF-C and PSA are also present in semen, which can affect reproduction, especially fertility. The researchers also found that cathepsin D can activate VEGF-C and VEGF-D. Researchers have previously known that cathepsin D is involved in the formation of metastasis, but lack a detailed understanding of its mechanism of action. Jeltsch said: "These new findings provide a lot of new information about lymphangiogenesis and the function of vascular endothelial growth factors, especially their role in prostate cancer and reproductive biology."

  "In the future, our findings may not only help develop new anti-cancer drugs, but may also help identify and treat mechanisms related to infertility."